Mylan Inc. Registration Rights Agreement $750,000,000 4.550% Senior Notes Due 2028 $750,000,000 5.200% Senior Notes Due 2048Registration Rights Agreement • April 9th, 2018 • Mylan N.V. • Pharmaceutical preparations • New York
This Registration Rights Agreement dated April 9, 2018 (this “Agreement”) is entered into by and among Mylan Inc., a Pennsylvania corporation (the “Company”), Mylan N.V., a public limited liability company (naamloze vennootschap) incorporated and existing under the laws of the Netherlands (the “Initial Guarantor”), and Deutsche Bank Securities Inc., J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives (the “Representatives”) of the several purchasers named in Schedules I(a) and I(b) to the Purchase Agreement (as defined below) (the “Initial Purchasers”).
TRANSITION AND SUCCESSION AGREEMENTTransition and Succession Agreement • May 10th, 2017 • Mylan N.V. • Pharmaceutical preparations • Pennsylvania
THIS TRANSITION AND SUCCESSION AGREEMENT (this “Agreement”) is entered into effective as of the 24th day of March, 2017, by and between Mylan Inc., a Pennsylvania corporation (the “Company”), and Daniel M. Gallagher (the “Executive”).
COMMERCIAL PAPER DEALER AGREEMENT among MYLAN INC., as Issuer MYLAN N.V., as Guarantor and as DealerCommercial Paper Dealer Agreement • July 30th, 2018 • Mylan N.V. • Pharmaceutical preparations • New York
This agreement (the “Agreement”) sets forth the understandings among the Issuer, the Guarantor and the Dealer, each named on the cover page hereof, in connection with the issuance and sale by the Issuer of its short-term promissory notes (the “Notes”) through the Dealer.
ContractSupplemental Indenture • November 19th, 2020 • Mylan II B.V. • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of November 16, 2020, among Utah Acquisition Sub Inc., a Delaware corporation (“Acquisition Sub”), Mylan II B.V., a private limited liability company incorporated and existing under the laws of the Netherlands (“Mylan II B.V.”), Mylan Inc., a Pennsylvania corporation (“Mylan Inc.”), Viatris Inc. (formerly known as Upjohn Inc.), a Delaware corporation (“Viatris Inc.” and, together with Mylan II B.V. and Mylan Inc., the “Note Guarantors”), and Citibank, N.A., London Branch, as trustee under the Indenture referred to below (the “Trustee”).
REVOLVING CREDIT AGREEMENT dated as of November 22, 2016 among MYLAN N.V., as Borrower and The Guarantors party hereto and BANK OF AMERICA, N.A., as Administrative Agent and the Lenders and the Issuing Banks party hereto MERRILL LYNCH, PIERCE, FENNER...Revolving Credit Agreement • March 1st, 2017 • Mylan N.V. • Pharmaceutical preparations • New York
This REVOLVING CREDIT AGREEMENT (this “Agreement”) is dated as of November 22, 2016 among MYLAN N.V., a public limited liability company (naamloze vennootschap) incorporated and existing under the laws of the Netherlands, with its corporate seat (statutaire zetel) in Amsterdam, the Netherlands and registered with the Dutch chamber of commerce under number 61036137 (the “Borrower”), certain Affiliates and Subsidiaries of the Borrower from time to time party hereto as Guarantors, each Lender and Issuing Bank from time to time party hereto, and BANK OF AMERICA, N.A., as Administrative Agent.
ContractExecutive Employment Agreement • February 27th, 2019 • Mylan N.V. • Pharmaceutical preparations • New York
This Third Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into on February 25, 2019, to be effective as of April 1, 2019 (the “Effective Date”), by and between Mylan Inc. (the “Company” or “Mylan”) and Rajiv Malik (“Executive”).
TERM CREDIT AGREEMENT dated as of November 22, 2016 among MYLAN N.V., as Borrower and the Guarantors party hereto and GOLDMAN SACHS BANK USA, as Administrative Agent and the Lenders party hereto GOLDMAN SACHS BANK USA, MERRILL LYNCH, PIERCE, FENNER &...Term Credit Agreement • March 1st, 2017 • Mylan N.V. • Pharmaceutical preparations • New York
This TERM CREDIT AGREEMENT (this “Agreement”) is dated as of November 22, 2016 among MYLAN N.V., a public limited liability company (naamloze vennootschap) incorporated and existing under the laws of the Netherlands, with its corporate seat (statutaire zetel) in Amsterdam, the Netherlands and registered with the Dutch chamber of commerce under number 61036137 (the “Borrower”), certain Affiliates and Subsidiaries of the Borrower from time to time party hereto as Guarantors, each Lender from time to time party hereto, and GOLDMAN SACHS BANK USA, as Administrative Agent.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 27th, 2019 • Mylan N.V. • Pharmaceutical preparations • Pennsylvania
This Executive Employment Agreement (the “Agreement”) is dated as of February 25, 2019, and effective as of April 1, 2019 (the “Effective Date”), by and between Mylan Inc. (the “Company” or “Mylan”) and Kenneth S. Parks (“Executive”).
MYLAN INC., as Issuer, MYLAN N.V. as Guarantor and THE BANK OF NEW YORK MELLON, as Trustee FIRST SUPPLEMENTAL INDENTURE DATED as of FEBRUARY 27, 2015 TO THE INDENTURE DATED as of December 21, 2012First Supplemental Indenture • February 27th, 2015 • Mylan B.V. • Pharmaceutical preparations • New York
First Supplemental Indenture (this “Supplemental Indenture”), dated as of February 27, 2015, among Mylan N.V., a public limited liability company (naamloze vennootschap) organized and existing under the laws of the Netherlands (the “Guarantor”), Mylan Inc., a Pennsylvania corporation (the “Company”), and The Bank of New York Mellon, as trustee under the Indenture referred to below (the “Trustee”).
AMENDMENT NO. 2 TO REVOLVING CREDIT AGREEMENTRevolving Credit Agreement • June 17th, 2020 • Mylan N.V. • Pharmaceutical preparations • New York
This REVOLVING CREDIT AGREEMENT (this “Agreement”) is dated as of July 27, 2018 among MYLAN INC., a Pennsylvania corporation (the “Borrower”), MYLAN N.V., a public limited liability company (naamloze vennootschap) incorporated and existing under the laws of the Netherlands, with its corporate seat (statutaire zetel) in Amsterdam, the Netherlands and registered with the Dutch chamber of commerce under number 61036137 (the “Parent” and a “Guarantor”), certain Affiliates and Subsidiaries of the Parent from time to time party hereto as Guarantors, each Lender and Issuing Bank from time to time party hereto, and BANK OF AMERICA, N.A., as Administrative Agent.
MYLAN INC., as Issuer, MYLAN N.V. as Guarantor and THE BANK OF NEW YORK MELLON, as Trustee SECOND SUPPLEMENTAL INDENTURE DATED as of FEBRUARY 27, 2015 TO THE INDENTURE DATED as of NOVEMBER 29, 2013Second Supplemental Indenture • February 27th, 2015 • Mylan B.V. • Pharmaceutical preparations • New York
Second Supplemental Indenture (this “Supplemental Indenture”), dated as of February 27, 2015, among Mylan N.V., a public limited liability company (naamloze vennootschap) organized and existing under the laws of the Netherlands (the “Guarantor”), Mylan Inc., a Pennsylvania corporation (the “Company”), and The Bank of New York Mellon, as trustee under the Indenture referred to below (the “Trustee”).
SEPARATION AND DISTRIBUTION AGREEMENT by and between PFIZER INC. and UPJOHN INC. Dated as of July 29, 2019Separation and Distribution Agreement • July 29th, 2019 • Mylan N.V. • Pharmaceutical preparations • Delaware
This SEPARATION AND DISTRIBUTION AGREEMENT, dated as of July 29, 2019, is by and between Pfizer Inc., a Delaware corporation (“Pluto”), and Upjohn Inc., a Delaware corporation (“Spinco”). Capitalized terms used herein and not otherwise defined shall have the respective meanings assigned to them in Article I hereof.
BRIDGE CREDIT AGREEMENT dated as of February 10, 2016 among MYLAN N.V., as Borrower and the Guarantors party hereto and DEUTSCHE BANK AG CAYMAN ISLANDS BRANCH, as Administrative Agent and the Lenders party hereto DEUTSCHE BANK SECURITIES INC. and...Bridge Credit Agreement • February 17th, 2016 • Mylan N.V. • Pharmaceutical preparations • New York
This BRIDGE CREDIT AGREEMENT (this “Agreement”) is dated as of February 10, 2016 among MYLAN N.V., a public limited liability company (naamloze vennootschap) incorporated and existing under the laws of the Netherlands, with its corporate seat (statutaire zetel) in Amsterdam, the Netherlands and registered with the Dutch chamber of commerce under number 61036137 (the “Borrower”), certain Affiliates and Subsidiaries of the Borrower from time to time party hereto as Guarantors, each Lender from time to time party hereto, and DEUTSCHE BANK AG CAYMAN ISLANDS BRANCH, as Administrative Agent.
SHAREHOLDER AGREEMENTShareholder Agreement • February 27th, 2015 • Mylan B.V. • Pharmaceutical preparations • New York
This Shareholder Agreement (this “Agreement”) is dated and effective as of February 27, 2015 between and among Mylan N.V., a public limited liability corporation (naamloze vennootschap) organized under the Laws of the Netherlands (“New Mylan”), Abbott Laboratories, an Illinois corporation (“Abbott”), Laboratoires Fournier S.A.S., a simplified corporation (Société par actions simplifiée) organized under the Laws of France (“Abbott France”), Abbott Established Products Holdings (Gibraltar) Limited, a private company limited by shares organized under the Laws of Gibraltar (“Abbott Gibraltar”), and Abbott Investments Luxembourg S.à r.l., a Luxembourg private limited company (Société à responsabilité limitée) organized under the Laws of Luxembourg (“Abbott Luxembourg,” and together with Abbott, Abbott France and Abbott Gibraltar and each of their respective Permitted Transferees (as defined below), the “Abbott Shareholders”). New Mylan and the Abbott Shareholders are referred to in this Agr
AMENDMENT NO. 3 TO TERM CREDIT AGREEMENTTerm Credit Agreement • February 26th, 2016 • Mylan N.V. • Pharmaceutical preparations • New York
AMENDMENT NO. 3 (this “Amendment”) dated as of February 22, 2016 to the Term Credit Agreement dated as of December 19, 2014 (as amended by (x) Amendment No. 1 to Term Credit Agreement dated as of May 1, 2015, and (y) Amendment No. 2 to Term Credit Agreement dated as of October 28, 2015, the “Credit Agreement”), among MYLAN INC. (the “Borrower”), MYLAN N.V., as a guarantor (the “Company”), the other borrowers and guarantors from time to time party thereto, the Lenders party thereto from time to time (the “Lenders”) and BANK OF AMERICA, N.A., as Administrative Agent (the “Agent”).
AMENDMENT NO. 3 TO THE SEPARATION AND DISTRIBUTION AGREEMENTSeparation and Distribution Agreement • November 6th, 2020 • Mylan N.V. • Pharmaceutical preparations
This Amendment No. 3 (this “Amendment”) to the Separation and Distribution Agreement, dated as of July 29, 2019, as amended (the “Agreement”), is made as of September 18, 2020 by and between Pfizer Inc., a Delaware corporation (“Pluto”) and Upjohn Inc., a Delaware corporation and wholly owned Subsidiary of Pluto (“Spinco”). Each of the foregoing parties is referred to herein as a “Party” and collectively as the “Parties.”
SHAREHOLDER AGREEMENTShareholder Agreement • February 17th, 2016 • Mylan N.V. • Pharmaceutical preparations • New York
This Shareholder Agreement (this “Agreement”) is dated and effective as of 10 February 2016 by and between Mylan N.V., a public limited liability company organized under the Laws of the Netherlands (“Mylan”), and Stena Sessan Rederi AB, a private limited liability company organized under the Laws of Sweden (the “Shareholder”). Mylan and the Shareholder are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
ContractSupplemental Indenture • November 19th, 2020 • Mylan II B.V. • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of November 16, 2020, among Utah Acquisition Sub Inc., a Delaware corporation (“Acquisition Sub”), Mylan II B.V., a private limited liability company incorporated and existing under the laws of the Netherlands (“Mylan II B.V.”), Mylan Inc., a Pennsylvania corporation (“Mylan Inc.” and, together with Acquisition Sub and Mylan II B.V., the “Guaranteeing Subsidiaries”), Viatris Inc., a Delaware corporation, Upjohn Finance B.V., a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) incorporated and existing under the laws of the Netherlands (the “Issuer”) and Citibank, N.A., London Branch, as trustee under the Indenture referred to below (the “Trustee”).
ContractExecutive Employment Agreement • May 11th, 2020 • Mylan N.V. • Pharmaceutical preparations • New York
This Executive Employment Agreement (this “Agreement”) is entered into on April 15, 2020, by and between Mylan N.V., Mylan Inc. (the “Company”) and Robert J. Coury (the “Executive”).
CALL OPTION AGREEMENTCall Option Agreement • April 3rd, 2015 • Mylan N.V. • Pharmaceutical preparations
This CALL OPTION AGREEMENT (the “Agreement”) dated as of April 3, 2015, is made by and between Stichting Preferred Shares Mylan, a foundation (stichting) incorporated under the laws of the Netherlands (the “Foundation”) and Mylan N.V., a public limited liability company (naamloze vennootschap) incorporated under the laws of the Netherlands (the “Company”).
Reference is made to the Third Amended and Restated Executive Employment Agreement, effective as of January 1, 2014 (the “Employment Agreement”), between Robert J. Coury (“Chairman”) and Mylan Inc. (“Mylan US”). Capitalized terms used but not defined...Executive Employment Agreement • August 9th, 2016 • Mylan N.V. • Pharmaceutical preparations • New York
This letter agreement shall be effective as of the date first written above (the “Effective Date”) and shall terminate at the close of business on the fifth anniversary of the Transition Date (“Initial Term”), unless earlier terminated in accordance with the terms of this letter agreement or extended by mutual agreement of Mylan NV and Chairman.
Performance-Based Restricted Stock Unit Award AgreementPerformance-Based Restricted Stock Unit Award Agreement • May 10th, 2017 • Mylan N.V. • Pharmaceutical preparations • Pennsylvania
Mylan N.V. (the “Company”) hereby grants to [__] (the “Participant”), effective as of [__] (the “Grant Date”), the performance-based restricted stock unit award (the “Performance RSUs”) as set forth in this Award Agreement. The Performance RSUs are subject to the terms and conditions set forth in this Award Agreement and in the Company’s 2003 Long-Term Incentive Plan, as amended (the “Plan”). In the event of any inconsistency between the terms of this Award Agreement and the terms of the Plan, the terms of the Plan shall govern except to the extent specifically set forth herein. Capitalized terms used but not defined in this Award Agreement (including Exhibit A hereto) shall have the meanings ascribed to them in the Plan. Notwithstanding the foregoing, the Performance RSUs shall be subject to any term of any employment agreement between the Company (or any Subsidiary) and the Participant that specifically references this Award Agreement (but, for the avoidance of doubt, shall not be su
ContractSupplemental Indenture • November 19th, 2020 • Mylan II B.V. • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of November 16, 2020, among Utah Acquisition Sub Inc., a Delaware corporation (“Acquisition Sub”), Mylan II B.V., a private limited liability company incorporated and existing under the laws of the Netherlands (“Mylan II B.V.”), Mylan Inc., a Pennsylvania corporation (“Mylan Inc.” and, together with Acquisition Sub and Mylan II B.V., the “Guaranteeing Subsidiaries”), each a subsidiary of Viatris Inc., a Delaware corporation (the “Company”), the Company and The Bank of New York Mellon, as trustee under the Indenture referred to below (the “Trustee”).
AMENDMENT NO. 1 TO THE SEPARATION AND DISTRIBUTION AGREEMENTSeparation and Distribution Agreement • May 11th, 2020 • Mylan N.V. • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”) to the Separation and Distribution Agreement, dated as of July 29, 2019 (the “Agreement”), is made as of February 18, 2020, by and between Pfizer Inc., a Delaware corporation (“Pfizer”), and Upjohn Inc., a Delaware corporation and wholly owned Subsidiary of Pfizer (“Upjohn”, and together with Pfizer, the “Parties”, and each, a “Party”).
ContractSupplemental Indenture • November 19th, 2020 • Mylan II B.V. • Pharmaceutical preparations • New York
FOURTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of November 16, 2020, among Mylan Inc., a Pennsylvania corporation (“Mylan Inc.”), Utah Acquisition Sub Inc., a Delaware corporation (“Acquisition Sub”), Mylan II B.V., a private limited liability company incorporated and existing under the laws of the Netherlands (“Mylan II B.V.”), Viatris Inc. (formerly known as Upjohn Inc.), a Delaware corporation (“Viatris Inc.” and, together with Acquisition Sub and Mylan II B.V., the “Note Guarantors”), and The Bank of New York Mellon, as trustee under the Indenture referred to below (the “Trustee”).
MYLAN N.V. 2003 LONG-TERM INCENTIVE PLAN STOCK OPTION AGREEMENTStock Option Agreement • May 7th, 2019 • Mylan N.V. • Pharmaceutical preparations • Pennsylvania
[_____] (the “Optionee”) is granted, effective as of the [_____] day of [_____], [_____] (the “Date of Grant”), options (the “Options”) to purchase ordinary shares of Mylan N.V. (the “Option Shares”) pursuant to the 2003 Long-Term Incentive Plan, as amended to date (the “Plan”), of Mylan N.V. (the “Corporation”). The Options are subject to the terms and conditions set forth below and in the Plan, which is a part of this Stock Option Agreement (the “Agreement”). To the extent that there is a conflict between the terms of the Plan and this Agreement, the terms of the Plan shall govern, except as specifically set forth herein. Any term not defined herein shall have the meaning assigned to such term in the Plan.
BUSINESS COMBINATION AGREEMENT by and among PFIZER INC., UPJOHN INC., UTAH ACQUISITION SUB INC., MYLAN N.V., MYLAN I B.V. and MYLAN II B.V. Dated as of July 29, 2019Business Combination Agreement • July 29th, 2019 • Mylan N.V. • Pharmaceutical preparations • Delaware
This BUSINESS COMBINATION AGREEMENT (this “Agreement”) dated as of July 29, 2019, is by and among Pfizer Inc., a Delaware corporation (“Pluto”), Upjohn Inc., a Delaware corporation and wholly owned Subsidiary of Pluto (“Spinco”), Utah Acquisition Sub Inc., a Delaware corporation and an indirectly wholly owned Subsidiary of Spinco (“Spinco Sub” and together with Spinco, the “Spinco Parties”), Mylan N.V., a public company with limited liability incorporated under the laws of the Netherlands (“Utah”), Mylan I B.V., a company incorporated under the laws of the Netherlands and a direct wholly owned subsidiary of Utah (“Utah Newco”), Mylan II B.V., a company incorporated under the laws of the Netherlands and a direct wholly owned subsidiary of Utah Newco (“Utah Newco Sub” and together with Utah and Utah Newco, the “Utah Parties”). Each of the foregoing parties is referred to herein as a “Party” and collectively as the “Parties.”
MYLAN INC., as Issuer, MYLAN N.V. as Guarantor and THE BANK OF NEW YORK MELLON, as Trustee THIRD SUPPLEMENTAL INDENTURE DATED as of FEBRUARY 27, 2015 TO THE INDENTURE DATED as of SEPTEMBER 15, 2008Third Supplemental Indenture • February 27th, 2015 • Mylan B.V. • Pharmaceutical preparations • New York
Third Supplemental Indenture (this “Supplemental Indenture”), dated as of February 27, 2015, among Mylan N.V., a public limited liability company (naamloze vennootschap) organized and existing under the laws of the Netherlands (the “Guarantor”), Mylan Inc., a Pennsylvania corporation (the “Company”), and The Bank of New York Mellon, as trustee under the Indenture referred to below (the “Trustee”).
THE BANK OF NEW YORK MELLON, as Trustee THIRD SUPPLEMENTAL INDENTURE DATED as of March 12, 2015 TO THE INDENTURE DATED as of NOVEMBER 29, 2013Third Supplemental Indenture • May 8th, 2015 • Mylan N.V. • Pharmaceutical preparations • New York
Third Supplemental Indenture (this “Supplemental Indenture”), dated as of March 12, 2015, among Mylan N.V., a public limited liability company (naamloze vennootschap) organized and existing under the laws of the Netherlands (the “Parent”), Mylan Inc., a Pennsylvania corporation (the “Issuer”), and The Bank of New York Mellon, as trustee under the Indenture referred to below (the “Trustee”).
AMENDMENT NO. 1 TO BRIDGE CREDIT AGREEMENTBridge Credit Agreement • May 1st, 2015 • Mylan N.V. • Pharmaceutical preparations • New York
AMENDMENT dated as of April 29, 2015 (this “Amendment”) to the Bridge Credit Agreement dated as of April 24, 2015 (the “Credit Agreement”), among MYLAN N.V. (the “Borrower”), the guarantors party thereto, the Lenders party thereto from time to time (the “Lenders”) and GOLDMAN SACHS BANK USA, as Administrative Agent (the “Agent”).
SETTLEMENT AGREEMENTSettlement Agreement • August 21st, 2017 • Mylan N.V. • Pharmaceutical preparations
This Settlement Agreement (“Agreement”) is entered into among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General (“OIG-HHS”) of the Department of Health and Human Services (“HHS”), Mylan Inc. and Mylan Specialty L.P. (collectively, “Mylan”), and Relators identified in the cases listed in Paragraph B of the Recitals to this Agreement (“Relators”) (hereafter collectively referred to as “the Parties”), through their authorized representatives.
MYLAN N.V. 2003 LONG-TERM INCENTIVE PLAN STOCK OPTION AGREEMENTStock Option Agreement • May 11th, 2020 • Mylan N.V. • Pharmaceutical preparations • Pennsylvania
[ ] (the “Optionee”) is granted, effective as of the grant date [ ], options (the “Options”) to purchase ordinary shares (the “Shares”) of Mylan N.V. (the “Option Shares” or “Shares”) pursuant to the 2003 Long-Term Incentive Plan, as amended to date (the “Plan”) of Mylan N.V. (the “Company”) in respect of the Optionee’s service as a member of the Board. The Options are subject to the terms and conditions set forth below and in the Plan, which is a part of this Stock Option Agreement (this “Award Agreement”). To the extent that there is a conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern. Any term not defined herein shall have the meaning assigned to such term in the Plan.
AMENDMENT NO. 1 TO AMENDED AND RESTATED RECEIVABLES PURCHASE AGREEMENTReceivables Purchase Agreement • August 9th, 2016 • Mylan N.V. • Pharmaceutical preparations • New York
This AMENDMENT NO. 1 TO AMENDED AND RESTATED RECEIVABLES PURCHASE AGREEMENT, dated as of May 20, 2016 (this “Amendment”), is among MYLAN PHARMACEUTICALS INC. (“MPI”), individually and as initial servicer (in such capacity, the “Servicer”), MYLAN SECURITIZATION LLC (“Seller”), VICTORY RECEIVABLES CORPORATION (“Victory”), as a conduit purchaser (in such capacity, the “Conduit Purchaser”), PNC BANK, NATIONAL ASSOCIATION (“PNC”), as a committed purchaser, THE BANK OF TOKYO-MITSUBISHI UFJ, LTD., NEW YORK BRANCH (“BTMUNY”), as a committed purchaser (each of PNC and BTMUNY in the capacity of a committed purchaser, individually, a “Committed Purchaser” and collectively, the “Committed Purchasers” and collectively with the Conduit Purchaser, the “Purchasers”), PNC, as a purchaser agent, BTMUNY, as a purchaser agent (each of PNC and BTMUNY in the capacity of a purchaser agent, individually, a “Purchaser Agent” and collectively, the “Purchaser Agents”), BTMUNY, as agent on behalf of the Secured P
AMENDMENT LETTERMulticurrency Term and Revolving Credit Facilities Agreement • November 9th, 2016 • Mylan N.V. • Pharmaceutical preparations
AMENDMENT NO. 1 TO REVOLVING CREDIT AGREEMENTRevolving Credit Agreement • May 7th, 2015 • Mylan N.V. • Pharmaceutical preparations • New York
AMENDMENT dated as of May 1, 2015 to the Revolving Credit Agreement dated as of December 19, 2014 (the “Credit Agreement”), among MYLAN INC. (the “Borrower”), MYLAN N.V. (the “Company”), the other borrowers and guarantors party thereto, the Lenders party thereto from time to time (the “Lenders”) and BANK OF AMERICA, N.A., as Administrative Agent (the “Agent”).
